On September 25, Bristol-Myers Squibb Company (NYSE:BMY) announced milestone results from its Phase 3 EXCALIBER-RRMM trial evaluating Zenbexus in combination with daratumumab and dexamethasone (ZDd) for relapsed or refractory multiple myeloma. At a median follow-up of 15.7 months across 420 patients, ZDd demonstrated a statistically significant improvement in minimal residual disease (MRD)-negative complete response rates compared to the standard DVd regimen. Simultaneously published in The Lancet Oncology, these data mark the first multiple myeloma therapy to demonstrate superiority on an MRD-negative complete response primary endpoint, providing clinical validation for BMS’s targeted protein degradation platform.
You May Also Want To Read: Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
Bull Case: Zenbexus Validates Growth Portfolio Strategy
The pivotal EXCALIBER-RRMM readout directly strengthens BMS’s core bull thesis by validating its proprietary CELMoD platform and accelerating its portfolio transformation. The clinical success of Zenbexus provides a dedicated catalyst to bolster BMY’s Growth Portfolio, which generated $7.6 billion in Q2 2026, a 15% year-over-year increase, driven by key therapies including Opdivo Qvantig, Reblozyl, and Breyanzi.
By demonstrating superior MRD-negativity, Zenbexus establishes a high-margin commercial runway in oncology that can help offset ongoing revenue decay in the company’s $5.4 billion Legacy Portfolio, where brands face continuous generic pressure. Supported by Q2 total revenues reaching $13.0 billion (up 6%) and strong operating cash flow, Bristol-Myers Squibb Company possesses the financial capacity to back late-stage pipeline launches. Management underscored this operational momentum by raising full-year 2026 revenue guidance to $49.0–$50.0 billion and non-GAAP EPS expectations to $6.75–$7.00, despite increasing anticipated operating expenses to $16.5 billion to fund ongoing R&D and commercialization efforts.
Bear Case: High Commercial Expectations Amid Legacy Erosion and Cost Ramps
While the EXCALIBER-RRMM trial highlights technical innovation, bears contend that commercializing novel oncology assets carries elevated execution and financial risk. BMY is aggressively funding product launches and late-stage development, reflected in non-GAAP R&D expenditures of $2.3 billion and SG&A expenses rising 8% to $1.8 billion in Q2, which contributed to a GAAP gross margin decline from 72.5% to 71.3%.
Furthermore, BMY must navigate ongoing generic competition that eroded legacy sales by 4% in Q2, meaning Zenbexus and adjacent growth drivers face a steep slope just to preserve long-term top-line stability. If adoption of new regimens lags or if development costs for supporting CELMoD indications escalate, the company’s capital structure has less cushion to absorb clinical or regulatory delays while simultaneously servicing debt and funding raised expense targets.
Don’t Miss: Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline
Conclusion
The EXCALIBER-RRMM trial results provide an important clinical milestone that validates Bristol-Myers Squibb Company’s targeted protein degradation technology. If BMS successfully translates these late-breaking Phase 3 data into rapid market adoption, Zenbexus offers a high-value commercial growth engine necessary to absorb ongoing generic headwinds and sustain the momentum reflected in the company’s upgraded 2026 financial guidance.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
